AgingNCT00299624
Effect of Aging on Haemostasis Parameters
An observational study of Aging, run by Hopital Lariboisière at 2 sites in France.
Trial summary
Aging is an independent risk factor, without any clear explanation. The primary aim of the study is to depict the effect of aging on the coagulation fibrinolysis parameters and microparticles. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Aging
- How many people
- 100 participants
- Where
- 2 sitesFrance
- Study dates
- Oct 2005to Aug 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Stable patients without overt acute clinical event, not receiving antiplatelet or anticoagulant treatment
Who may be able to join
- age <40 2 groups : 1 : no history of VTE 2 : history of VTE
Who cannot join
- antiaggregant or anticoagulant therapy at curative dose
- arterial or thrombotic event in the last month
Trial locations and contacts
2 sites in 1 country.
France2 sites
Hopital Lariboisiere
Paris, 75010
Hopital Lariboisière
Paris, 75010
About this study
Official title: Identifying Morphological and Biological Biomarkers of the Venous Thromboembolic Risk Risk Related to Aging
Aging is an independent risk factor, without any clear explanation. The primary aim of the study is to depict the effect of aging on the coagulation fibrinolysis parameters and microparticles.
Read the detailed description
Patients older than 40, without any acute disease and not receiving any antiaggregant and anticoagulant therapy will be included in the study. Blood tests will be performed for coagulation, fibrinolysis and microparticles measurement.
- Conditions
- Aging
- Keywords
- venous thromboembolism risk,, elderly,, hypercoagulability, fibrinolysis, microparticles
- Medical subject headings
- Thrombophilia
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2006 (estimated)
- Study startOct 2005
- Primary completionAug 2006
- Study completionAug 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hopital Lariboisière
- Sponsor type
- University, hospital or other
- Investigators
- isabelle mahé, MD PhD, Principal investigator, MCU-PH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00299624
- Sponsor's protocol ID
- TAPH
- Status last verified
- Sep 2010
- First submitted
- 6 Mar 2006
- Last updated
- 14 Sep 2010
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identifying Morphological and Biological Biomarkers of the Venous Thromboembolic Risk Risk Related to Aging
- ClinicalTrials.gov ID
- NCT00299624
- Acronym / sponsor ID
- TAPH
- Conditions
- Aging
- Keywords
- venous thromboembolism risk,, elderly,, hypercoagulability, fibrinolysis, microparticles
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Hopital LariboisièreUniversity, hospital or other
- Study start
- Oct 2005
- Primary completion
- Aug 2006 (actual)
- Study completion
- Aug 2006 (actual)
- First posted
- 7 Mar 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aging is an independent risk factor, without any clear explanation. The primary aim of the study is to depict the effect of aging on the coagulation fibrinolysis parameters and microparticles.
Detailed description
Patients older than 40, without any acute disease and not receiving any antiaggregant and anticoagulant therapy will be included in the study. Blood tests will be performed for coagulation, fibrinolysis and microparticles measurement.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Stable patients without overt acute clinical event, not receiving antiplatelet or anticoagulant treatment
Key inclusion criteria (1 listed)
- age <40 2 groups : 1 : no history of VTE 2 : history of VTE
Key exclusion criteria (2 listed)
- antiaggregant or anticoagulant therapy at curative dose
- arterial or thrombotic event in the last month
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2010.
Related trials for Aging
Enrolling by invitationPhase 2
Tirzepatide and Organ-specific Biological Aging
Longevity, Preventive Medicine
Active, not recruiting
Emotional Well-being and Measures of Healthy Aging
Aging, Aging, Healthy
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Active, not recruiting
Vascular Aging and Lp299v Study in Healthy Adults
Vascular Aging
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
isabelle mahé, MD PhD principal investigator
MCU-PH
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aging, run by Hopital Lariboisière at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Sep 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2010.